Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection.

Tsuge M, Uchida T, Walsh K, Ishida Y, Tateno C, Kumar U, Glenn JS, Koh C, Heller T, Uprichard SL, Dahari H, Chayama K.

Viruses. 2019 Mar 15;11(3). pii: E263. doi: 10.3390/v11030263.

2.

A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C.

Koh C, Dubey P, Han MAT, Walter PJ, Garraffo HM, Surana P, Southall NT, Borochov N, Uprichard SL, Cotler SJ, Etzion O, Heller T, Dahari H, Liang TJ.

Antiviral Res. 2019 Mar;163:149-155. doi: 10.1016/j.antiviral.2019.01.017. Epub 2019 Jan 31.

PMID:
30711416
3.

Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.

Gambato M, Canini L, Lens S, Graw F, Perpiñan E, Londoño MC, Uprichard SL, Mariño Z, Reverter E, Bartres C, González P, Pla A, Costa J, Burra P, Cotler SJ, Forns X, Dahari H.

Liver Int. 2019 May;39(5):826-834. doi: 10.1111/liv.14014. Epub 2018 Dec 28.

PMID:
30499631
4.

Accounting for Space—Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models.

Kumberger P, Durso-Cain K, Uprichard SL, Dahari H, Graw F.

Viruses. 2018 Apr 17;10(4). pii: E200. doi: 10.3390/v10040200.

5.

Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics.

Ishida Y, Chung TL, Imamura M, Hiraga N, Sen S, Yokomichi H, Tateno C, Canini L, Perelson AS, Uprichard SL, Dahari H, Chayama K.

Hepatology. 2018 Aug;68(2):473-484. doi: 10.1002/hep.29891. Epub 2018 Jun 6.

6.

Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein Mechanisms.

Aunins TR, Marsh KA, Subramanya G, Uprichard SL, Perelson AS, Chatterjee A.

J Virol. 2018 May 14;92(11). pii: e02098-17. doi: 10.1128/JVI.02098-17. Print 2018 Jun 1.

7.

Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.

Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H.

Hepatol Commun. 2017 May 19;1(4):288-292. doi: 10.1002/hep4.1043. eCollection 2017 Jun.

8.

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.

Canini L, Imamura M, Kawakami Y, Uprichard SL, Cotler SJ, Dahari H, Chayama K.

PLoS One. 2017 Dec 7;12(12):e0187409. doi: 10.1371/journal.pone.0187409. eCollection 2017.

9.

The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?

Nguyen THT, Guedj J, Uprichard SL, Kohli A, Kottilil S, Perelson AS.

Sci Rep. 2017 Aug 31;7(1):10233. doi: 10.1038/s41598-017-09776-z.

10.

Modeling HCV cure after an ultra-short duration of therapy with direct acting agents.

Goyal A, Lurie Y, Meissner EG, Major M, Sansone N, Uprichard SL, Cotler SJ, Dahari H.

Antiviral Res. 2017 Aug;144:281-285. doi: 10.1016/j.antiviral.2017.06.019. Epub 2017 Jun 30.

11.

Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies.

Malespin M, Benyashvili T, Uprichard SL, Perelson AS, Dahari H, Cotler SJ.

Therap Adv Gastroenterol. 2017 Jan;10(1):68-73. doi: 10.1177/1756283X16672392. Epub 2016 Oct 17.

12.

Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report.

Hasin Y, Shteingart S, Dahari H, Gafanovich I, Floru S, Braun M, Shlomai A, Verstandig A, Dery I, Uprichard SL, Cotler SJ, Lurie Y.

World J Hepatol. 2016 Jul 18;8(20):858-62. doi: 10.4254/wjh.v8.i20.858.

13.

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Dahari H, Canini L, Graw F, Uprichard SL, Araújo ES, Penaranda G, Coquet E, Chiche L, Riso A, Renou C, Bourliere M, Cotler SJ, Halfon P.

J Hepatol. 2016 Jun;64(6):1232-9. doi: 10.1016/j.jhep.2016.02.022. Epub 2016 Feb 22.

14.

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T.

Lancet Infect Dis. 2015 Oct;15(10):1167-1174. doi: 10.1016/S1473-3099(15)00074-2. Epub 2015 Jul 16.

15.

Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach.

Graw F, Martin DN, Perelson AS, Uprichard SL, Dahari H.

J Virol. 2015 Jul;89(13):6551-61. doi: 10.1128/JVI.00016-15. Epub 2015 Apr 1.

16.

Hepatitis C virus Cell-to-cell Spread Assay.

Barretto N, Uprichard SL.

Bio Protoc. 2014 Dec 20;4(24). pii: e1365. doi: 10.21769/BioProtoc.1365.

17.

Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment.

Uprichard SL, Sainz B Jr.

Gut. 2015 Apr;64(4):690-1. doi: 10.1136/gutjnl-2014-308396. Epub 2014 Oct 6. No abstract available.

PMID:
25287483
18.

Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.

Sabahi A, Uprichard SL, Wimley WC, Dash S, Garry RF.

J Virol. 2014 Sep;88(18):10280-8. doi: 10.1128/JVI.00874-14. Epub 2014 Jul 2. Review.

19.

Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread.

Barretto N, Sainz B Jr, Hussain S, Uprichard SL.

J Virol. 2014 May;88(9):5050-61. doi: 10.1128/JVI.03241-13. Epub 2014 Feb 19.

20.

Establishment of mice with inheritable susceptibility to productive hepatitis C virus infection.

Uprichard SL.

Hepatology. 2014 May;59(5):2043-6. doi: 10.1002/hep.26949. Epub 2014 Mar 27. No abstract available.

PMID:
24277664

Supplemental Content

Loading ...
Support Center